X4 PHARMACEUTICALS, INC Capital Expenditures Incurred but Not yet Paid
X4 PHARMACEUTICALS, INC (XFOR) reported Capital Expenditures Incurred but Not yet Paid of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $500.00K.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for fiscal 2025 was $500.00K, a 85.71% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for fiscal 2024 was $3.50M.
- X4 PHARMACEUTICALS, INC capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $500.00K derived: sum of 2 quarters · filed 2026-03-17 | $500.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $3.50M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.50M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $3.50M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$17.00K derived: sum of 2 quarters · filed 2022-08-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $17.00K 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $2.05M 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $38.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |